Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo-Controlled, Double-Blind, Randomized Phase 2 Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe in Participants With Mild Dyslipidemia

NCT04770389 is registered in ClinicalTrials.gov with NewAmsterdam Pharma as lead sponsor.

NCT NCT04770389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04770389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo-Controlled, Double-Blind, Randomized Phase 2 Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe in Participants With Mild Dyslipidemia
Lead sponsor
NewAmsterdam Pharma
Phase
Phase 2
Overall status
Completed
Start date
February 23, 2021
Completion date
June 30, 2021
Enrollment
112 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidemias, high cholesterol, hypercholesterolemia